基于生物信息学分析WNT7B基因在肺腺癌中的表达及其临床意义

Analysis of the expression and clinical significance of WNT7B gene in lungadenocarcinoma based on bioinformatics

目的:基于生物信息学分析WNT7B基因在肺腺癌(LUAD)中的表达及其临床意义。方法:应用生物信息学方法评价WNT7B在LUAD中的诊断和预后预测价值。通过TCGA、GEO数据库研究WNT7B基因在肺癌中表达情况,并分析WNT7B基因在肺癌和非癌组织中表达差异及其表达与生存率、免疫细胞浸润之间的关系。应用STRING数据库筛选共表达基因并构建调控网络,将共表达基因进行基因本体论(GO)以及京东基因和基因组(KEGG)富集分析,同时应用cBioportal探究WNT7B基因突变对肺癌患者生存期的影响。结果:与正常肺组织相比,LUAD组织中WNT7B基因表达水平明显升高(P<0.01),WNT7B基因作为标志物的灵敏度为0.628。K-M生存分析显示,高表达WNT7B组预后较差(P<0.05)。GSEA揭示了5条与WNT7B基因相关的信号通路,WNT7B基因突变的LUAD患者总生存期(P=0.035 8)的预后预测作用不佳。此外,还发现WNT7B基因表达与免疫显著相关。结论:WNT7B基因有望成为LUAD诊断、预后评估和治疗的新靶点,但仍须进一步开展临床相关研究。

Objective:To analyze of the expression and clinical significance of WNT7B gene in lung adenocarcinoma(LUAD)based on bioinformatics.Methods:Bioinformatics methods were used to evaluate the diagnostic and prognostic value of WNT7B gene in LUAD.The expression of WNT7B gene in lung cancer was studied by TCGA and GEO databases,and the expression difference of WNT7B gene in lung cancer and non-cancer tissues and its relationship with survival rate and immune cell infiltration were analyzed.The STRING database was used to screen co-expressed genes and construct regulatory networks.The co-expressed genes were subjected to gene ontology(GO)and Jingdong gene and genome(KEGG)enrichment analysis.At the same time,cBioportal was used to explore the effect of WNT7B gene mutation on the survival of lung cancer patients.Results:Compared with normal lung tissue,the expression level of WNT7B gene in LUAD tissue was significantly increased(P<0.01),and the sensitivity of WNT7B gene as a marker was 0.628.K-M survival analysis showed that the high expression of WNT7 B group had a poor prognosis(P<0.05).GSEA revealed five WNT7B-related signaling pathways.The prognosis of LUAD patients with WNT7B gene mutation was poor(P=0.0358).In addition,it was also found that WNT7B expression was significantly associated with immunity.Conclusion:WNT7B gene can be used as a prognostic and diagnostic biomarker,which provides a deeper perspective for the treatment of LUAD and the development of prognostic markers.